Wanbury Limited reported its audited financial results for the year ended 31 March 2026, demonstrating a significant improvement in profitability and revenue. The pharmaceutical company recorded a net profit of ₹6,613.47 crore for FY26, a substantial increase from ₹3,053.01 crore in the previous year. Revenue from operations for the year rose to ₹65,026.83 crore, compared to ₹59,951.42 crore in FY25, driven by robust operational performance across its sole pharmaceutical segment.

Key Financial Performance

The annual results highlight a strong financial turnaround, with the company successfully managing costs and expanding its market presence. For the fourth quarter ended 31 March 2026, net profit stood at ₹2,170.49 crore, while revenue from operations was ₹16,457.86 crore. The board approved the audited financial results at its meeting held on 29 May 2026.

The table below summarises the key financial metrics for the year and quarter ended 31 March 2026:

Operational Highlights and Exceptional Items

Wanbury's operational efficiency is underscored by its two USFDA-approved manufacturing facilities located at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra). Notably, the Patalganga facility successfully cleared an MFDS-Korea inspection with zero observations in April 2026. The company reported an exceptional item of ₹360.39 crore for the quarter and year, primarily arising from an increase in gratuity and leave liabilities due to the implementation of new Labour Codes by the Government of India.

Taxation and Share Capital Updates

In compliance with the Finance Bill, 2026, Wanbury has decided to opt for the new tax regime effective from the financial year 2026-27. Consequently, the company re-measured its deferred tax assets and liabilities, recognising a write-off of ₹551.67 crore in the statement of profit and loss. Additionally, during the quarter, 47,400 equity shares were allotted upon the exercise of vested options under the Wanbury ESOP-2016, increasing the paid-up share capital by ₹4.74 crore. The auditor's report on the audited financial results carries an unmodified opinion.

Wanbury Limited has successfully completed the Korea FDA (Ministry of Food and Drug Safety - MFDS) regulatory inspection at its Patalganga manufacturing facility with zero observations, confirming cGMP compliance per international rules. The inspection was conducted from 7th April to 9th April by two inspectors over three days.

Inspection Details and Outcome

The Korea FDA inspection at the Patalganga site concluded without any regulatory issues, marking a significant achievement for the pharmaceutical company's quality assurance and regulatory compliance efforts. The zero observation outcome confirms the facility's adherence to current Good Manufacturing Practices (cGMP) as per international standards.

PIC Membership and Global Recognition

The Ministry of Food and Drug Safety (MFDS) is part of the Pharmaceutical Inspection Co-operation Scheme (PIC), which enhances the international recognition of this regulatory approval. This membership strengthens the global acceptance of the inspection standards and outcomes.

Multi-Site Regulatory Excellence

Wanbury's regulatory success extends across multiple facilities and international authorities. Both API manufacturing sites at Patalganga and Tanuku are USFDA approved and continue to maintain cGMP compliance. The company has achieved a consistent track record of zero observations across different regulatory bodies.

Infrastructure Development

The company is strengthening its infrastructure by adding a new state-of-the-art manufacturing block at its Andhra Pradesh site for new APIs, which is currently under validation and commercialisation. This expansion demonstrates Wanbury's commitment to enhancing its manufacturing capabilities and capacity.